SCHEMBL191463

SCHEMBL191463

COc1cccc(Oc2ccnc(Cl)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
CCR1 P32246 1/20 0.48
CCR5 P51681 1/20 0.48
CCR8 P51685 1/20 0.48
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
BRCA1 P38398 1/20 0.46
HBB P68871 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DYRK1A Q13627 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
RAB9A P51151 3/20 0.45
NFE2L2 Q16236 1/20 0.45
PIN1 Q13526 1/20 0.44
ROCK1 Q13464 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29792641 0.87
SCHEMBL287199 0.87
SCHEMBL191885 0.86 CCR1 (0.47) SMN1; SMN2CCR1CCR5CCR8ALDH1A1
SCHEMBL30864880 0.83 GRM5 (0.48) CCR1CCR5CCR8DYRK1ACLK4
SCHEMBL27314075 0.83 GRM5 (0.48) CCR1CCR5CCR8DYRK1ACLK4
SCHEMBL29048001 0.82 SCN5A (0.49) SMN1; SMN2MEN1KMT2AGRM5LMNA
SCHEMBL190319 0.82 LTA4H (0.48) SMN1; SMN2MEN1KMT2ARAB9ALMNA
SCHEMBL2599589 0.81 PIN1 (0.55) SMN1; SMN2ALDH1A1KDM4EMEN1BRCA1
Pyridine SCHEMBL28222133 0.81 CCR1 (0.50) CCR1CCR5CCR8DYRK1ACLK4
SCHEMBL1459485 0.79 MAOB (0.56) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024258591-A2 NOVEL INHIBITORS OF HISTONE DEMETHYLASES AND COMPOSITIONS AND METHODS THEREOF XIANG YIBIN (US) 2024-12-19 WO disclosed
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 SMN1; SMN2 2600/4885CCR1 4736/4885CCR5 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.